Home / Health / PE Treatment Trial Success: Vertex System Shows Promise
PE Treatment Trial Success: Vertex System Shows Promise
21 May
Summary
- Vertex system trial met primary endpoints for PE treatment.
- Significant haemodynamic recovery demonstrated with low adverse event rate.
- Proprietary TFX technology simplifies navigation and improves access.
Jupiter Endovascular announced positive pivotal trial results for its Vertex pulmonary embolectomy system, designed for treating pulmonary embolism (PE). The SPIRARE II trial, involving 123 patients, successfully met its primary endpoints, showcasing significant haemodynamic recovery.
The Vertex system achieved a notable reduction in the right ventricle to left ventricle (RV/LV) ratio within 48 hours. This demonstrated effective reversal of right heart strain, with a major adverse event rate of only 2.4%. The trial data was presented at the EuroPCR 2026 congress in Paris.
Catalin Toma, a co-principal investigator, noted the impressive results given the patient population's severity, with over half presenting in normotensive shock. Jupiter's Vertex system utilizes the proprietary transforming fixation (TFX) platform, designed to enhance navigation through the heart and into pulmonary arteries, addressing key challenges in PE thrombectomy.
Further analysis indicated that TFX thrombectomy led to meaningful right heart recovery beyond clot removal, evidenced by improvements in pulmonary artery pressures and vascular resistance. Jupiter's CEO emphasized that the trial's robust dataset supports a growing understanding of PE as a complex cardiovascular disease rooted in right heart dysfunction.
